MENU
+Compare
ARKG
ETF ticker: BATS
AS OF
Apr 3, 04:59 PM (EDT)
Price
$19.74
Change
-$1.13 (-5.41%)
Net Assets
936.86M

ARKG stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for ARKG with price predictions
Apr 02, 2025

Momentum Indicator for ARKG turns negative, indicating new downward trend

ARKG saw its Momentum Indicator move below the 0 level on March 28, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In of the 79 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ARKG turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for ARKG crossed bearishly below the 50-day moving average on March 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ARKG entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARKG's RSI Oscillator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARKG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Exact Sciences Corp (NASDAQ:EXAS), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Teladoc Health (NYSE:TDOC), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Market Cap

The average market capitalization across the ARK Genomic Revolution ETF ETF is 79.28B. The market cap for tickers in the group ranges from 45.49M to 2.69T. NVDA holds the highest valuation in this group at 2.69T. The lowest valued company is RPTX at 45.49M.

High and low price notable news

The average weekly price growth across all stocks in the ARK Genomic Revolution ETF ETF was 3%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was 90%. RPTX experienced the highest price growth at 6%, while VERV experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the ARK Genomic Revolution ETF ETF was -21%. For the same stocks of the ETF, the average monthly volume growth was -43% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 83
Price Growth Rating: 70
SMR Rating: 89
Profit Risk Rating: 89
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ARK ETF Trust155 West 19th Street, 5th FloorNew York
Phone
212-426-7040
Web
www.ark-funds.com